Zevra reported Q2 2025 revenue of $25.9M, supported by $21.5M in MIPLYFFA sales and $2.6M in reimbursements for arimoclomol from France’s EAP. Net income surged to $74.7M due to a $148.3M gain from PRV sale, offset partially by a $58.7M impairment charge.

Zevra Therapeutics reported a net revenue of $20.4 million for Q1 2025, a substantial increase from the previous year, primarily due to strong MIPLYFFA net revenue. Despite an operating loss, the company significantly improved its cash position to $217.0 million after the sale of its Pediatric Rare Disease Priority Review Voucher, positioning it for future commercial launches and development.

Zevra's Q4 2024 revenue was driven by MIPLYFFA sales, but overall revenue declined compared to Q4 2023 due to the absence of one-time sales milestone payments. The company continues to focus on expanding its pipeline and commercializing rare disease treatments. Operating expenses increased due to commercial launch activities, resulting in a higher net loss.

Zevra Therapeutics reported a net revenue of $3.7 million for Q3 2024, driven by reimbursements from the French expanded access program for arimoclomol and royalties from the AZSTARYS® license agreement. The company's cash, cash equivalents, and investments totaled $95.5 million. The FDA approval of MIPLYFFA capsules for NPC treatment was a major milestone.

Zevra Therapeutics reported Q2 2024 net revenue of $4.4 million, a decrease from $8.5 million in Q2 2023. The net loss for the quarter was $19.9 million, or $0.48 per share, compared to a net loss of $2.6 million, or $0.08 per share in the corresponding period of the previous year. The company's cash, cash equivalents, and investments totaled $49.3 million as of June 30, 2024. The company completed an underwritten public offering on August 12, 2024, resulting in pro forma June 30, 2024 total cash, cash equivalents and investments of $113.8 million.

Zevra Therapeutics reported a net revenue of $3.4 million for Q1 2024, compared to $3.2 million in Q1 2023. The net loss for Q1 2024 was $16.6 million, or $0.40 per share, compared to a net loss of $13.2 million, or $0.38 per share for Q1 2023. The company's cash, cash equivalents, and investments totaled $52.7 million as of March 31, 2024.

Zevra Therapeutics reported Q4 2023 net revenue of $13.2 million. The company is focusing on the launch of OLPRUVA, preparing for the launch of arimoclomol, and advancing the KP1077 development program.

Zevra Therapeutics reported a net revenue of $2.9 million for Q3 2023 and ended the quarter with $83.4 million in cash, cash equivalents, and investments. The company is focused on closing the proposed Acer acquisition, resubmitting the arimoclomol NDA, and completing the Phase 2 trial in idiopathic hypersomnia.

Zevra Therapeutics reported net revenue of $8.5 million for Q2 2023, driven by AZSTARYS milestone revenues, ongoing royalties from AZSTARYS, and the French early access program for arimoclomol. The company ended the quarter with $87.4 million in cash, cash equivalents, and investments.

Zevra Therapeutics reported a net revenue of $2.9 million for Q1 2023, supported by AZSTARYS® royalties and the arimoclomol early access program in France. The company's cash runway is expected to extend into 2026, with $95.3 million in cash, cash equivalents, and investments as of March 31, 2023.

Zevra Therapeutics reported a net revenue of $2.3 million for Q4 2022, primarily driven by reimbursements from the French early access program for arimoclomol, AZSTARYS® royalty revenues, and consulting fees. The company's cash, cash equivalents, and investments totaled $102.9 million as of December 31, 2022, extending the cash runway into 2026.

KemPharm reported Q3 2022 financial results with a net revenue of $2.9 million. The company is progressing with the arimoclomol NDA resubmission and advancing KP1077 for a Phase 2 clinical trial in IH. With $107.4 million in cash, the company's cash runway extends into 2026.

KemPharm reported Q2 2022 net revenue of $1.3 million and a net loss attributable to common stockholders of $24.0 million, which includes a one-time non-cash expense of $17.7 million related to the acquisition of arimoclomol.

KemPharm reported revenue of $4.0 million for Q1 2022, compared to $12.1 million in Q1 2021. The net loss attributable to common stockholders for Q1 2022 was ($1.9) million, or ($0.05) per basic and diluted share, compared to a net loss of ($47.7) million, or ($2.49) per basic and diluted share for the same period in 2021. Total cash, cash equivalents, marketable securities, and long-term investments were $119.1 million as of March 31, 2022.

KemPharm reported Q4 2021 revenue of $2.6 million and a net loss of ($2.7) million. The company's cash, cash equivalents, and long-term investments totaled $127.8 million as of December 31, 2021.

KemPharm reported Q3 2021 revenue of $2.0 million and a net loss of $0.05 per basic share. Total cash and cash equivalents were $131.5 million as of September 30, 2021. The U.S. commercial launch of AZSTARYS® was initiated on July 21, 2021.

KemPharm reported a strong second quarter with a revenue of $12.0 million and a net income of $6.2 million, driven by a $10 million milestone payment for DEA scheduling of SDX and $2.0 million in service fee revenue. The company also saw significant progress with the commercial launch of AZSTARYS and the classification of SDX as a Schedule IV controlled substance.

KemPharm reported a transformational first quarter of 2021 with the FDA approval of AZSTARYS, completion of financial restructuring, and re-listing on Nasdaq. The company reported revenue of $12.1 million and a net loss of $0.54 per share.

KemPharm reported revenue of $6.9 million, driven by a $5.0 million milestone payment and $1.9 million from research and development services. Net income for the quarter was $0.9 million, or $0.01 per share, compared to a net loss of $9.3 million for the same period in 2019. Cash and cash equivalents increased by $4.0 million to $6.6 million as of June 30, 2020.

KemPharm reported Q1 2020 revenue of $2.1 million from research and development services, and a net loss of $5.8 million, or $0.12 per share. The FDA's acceptance of the KP415 NDA triggered a $5 million milestone payment from GPC.

KemPharm reported Q4 2019 revenue of $1.4 million from research and development services, and a net loss of $6.0 million, or $0.18 per share. The company's cash and investments totaled $3.6 million as of December 31, 2019. They anticipate KP415 NDA submission in Q1 2020.